Please assess the completion status of the following clinical trial:

Trial Title: Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic~* treatment-naïve or have received no more than 3 systemic treatment regimen(s)~* Positive for translocation or inversion events involving the ROS1 gene~* Negative for translocation or inversion events involving the ALK gene~* Patients with brain metastases are eligible if asymptomatic, or if treated, must be neurologically stable for at least 2 weeks and are not taking any contraindicated medications~* Any prior treatment (chemotherapy, radiation \[except for palliative\], or surgery) must have been completed at least 2 weeks prior to initiation of study medication~* At least 1 measurable tumor lesion as per RECIST v1.1~* Female or male, 18 years of age or older~* ECOG performance status 0 to 1~* Adequate organ function~* Signed and dated informed consent~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including completion of the PRO measures~* Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment~Exclusion Criteria:~* Current treatment on another therapeutic clinical trial~* Prior therapy specifically directed against ALK or ROS1 fusion genes~* Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease~* known interstitial fibrosis or interstitial lung disease~* myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack within 3 months prior to start of study treatment~* Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade \>/=2, uncontrolled atrial fibrillation of any grade, or QTc \>470 msec~* Pregnant or breast feeding~* Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers~* Use of other anti-cancer drugs including traditional Chinese medicine on the SFDA list~* Evidence of active malignancy within last 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crizotinib (Type: EXPERIMENTAL): Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).